Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion

Human Gene Therapy

Volumn 9, Issue 10, 1998, Pages 1397-1407

  Cherington, Van ^a   Chiang, Gisela G ^a   McGrath, Claire A ^a   Gaffney, Anita ^a   Galanopoulos, Theofanis ^a   Merrill, Wilma ^a   Bizinkauskas, Christine B ^a   Hansen, Michael ^a   Sobolewski, Joyce ^a   Levine, Peter H ^b   Greenberger, Joel S ^a   Hurwitz, David R ^a  

^a ALG Company   (United States)

^b Memorial Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 9; VIRUS VECTOR; VITAMIN K GROUP;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING; BONE MARROW; CULTURE MEDIUM; FEMALE; GENE TARGETING; GENE THERAPY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PLASMA; RETROVIRUS; STROMA CELL;

EID: 17344364147     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.10-1397     Document Type: Article

References (12)

1. ANKLESARIA, P., FITZGERALD, T.J., KASE, K., OHARA, A., and GREENBERGER, J.S. (1989). Improved hematopoiesis in anemic Sl/Sld mice by splenectomy and therapeutic transplantation of a hematopoietic microenvironment. Blood 74(3), 1144-1151.
2. ANKLESARIA, P., KASE, K., GLOWACKI, J., HOLLAND, C.A., SAKAKEENY, M.A., WRIGHT, J.A., FITZGERALD, T.J., LEE, C.Y., and GREENBERGER, J.S. (1987). Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc. Natl. Acad. Sci. U.S.A. 84(21), 7681-7685.
3. AXELROD, J.H., READ, M.S., BRINKHOUS, K.M., and VERMA, I.M. (1990). Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophific dogs. Proc. Natl. Acad. Sci. U.S.A. 87(13), 5173-5177.
4. BOULIKAS, T. (1996). Gene therapy to human diseases: Ex vivo and in vivo studies (Review). Int. J. Oncol. 9(6), 1239-1251.
5. BRENNER, M., KRANCE, R., HESLOP, H.E., SANTANA, V., IHLE, J., RIBEIRO, R., ROBERTS, W.M., MAHMOUD, H., BOYETT, J., MOEN, R.C., and KLINGEMANN, H.-G. (1994). Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in the first complete remission. Hum. Gene Ther. 5, 481-499.
6. BRETTLER, D.B., and LEVINE, P.H. (1994). Clinical manifestations and therapy of inherited coagulation factor deficiencies. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd Ed. R.W. Colman, J. Hirsh, V.J. Marder, and E.W. Salzman, eds. (Lippincott, Philadelphia, PA) pp. 169-183.
7. BRINKHOUS, K.M. (1992). Gene transfer in the hemophilias: Retrospect and prospect. Thromb Res 67(3), 329-338.
8. CHIANG, G.G., McGRATH, C.A., NATALE, A., GALANOPOULOS, T., CHERINGTON, V., BIZINKAUSKAS, C.B., MERRILL, W., HANSEN, M., LEVINE, P.H., GREENBERGER, J.S., and HURWITZ, D.R. (1998). Retroviral vector transduced autologous bone marrow stromal cells express human growth hormone or human factor IX into the circulation of reinfused dogs. In Hematopoietic Microenvironment. A. Keating and J.S. Greenberger, eds. (Humana Press, London) (in press).
9. DEISSEROTH, A.B., KAVANAGH, J., and CHAMPLIN, R. (1994). Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer A pilot trial. Hum. Gene Ther. 5, 1507-1522.
10. DEISSEROTH, A.B., HOLMES, F., HORTOBAGYI, G., and CHAMPLIN, R. (1996). Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: A pilot study. Hum. Gene Ther. 7, 401-416.
11. DING, L.M., SAYLORS, R., and MUNSHI, N.C. (1995). The stromal cells as a vehicle for ex vivo gene therapy. Blood 86(Suppl. 1), 409a.
12. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90(8), 3539-3543.